Post-Transplant Lymphoproliferative Disorder · line 2 · Rituximab maintenance after EBV+ B-PTLD response (PTLD-1 sequential approach)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 2 |
|---|---|
| Track | standard |
| Linked regimen | REG-RITUXIMAB-MAINTENANCE-PTLD |
| ID | IND-PTLD-MAINTENANCE-RITUXIMAB |
|---|---|
| Type | Indication |
| Status | reviewed 2026-04-27 | pending_clinical_signoff |
| Diseases | DIS-PTLD |
| Sources | SRC-ESMO-LYMPHOMA-2025 SRC-NCCN-BCELL-2025 |
Notes
STUB. PTLD-1 sequential approach is the modern standard. Funded via НСЗУ. Always co-manage with transplant team for ongoing IS modulation.
Used By
Algorithms
ALGO-PTLD-2L- ALGO-PTLD-2L